News & Insights

by GCT Admin

New Preclinical Data: GCT-007 + Immune Checkpoint Inhibitors Show Synergistic Activity in Childhood Diffuse Midline Glioma

KEY MESSAGE: Global Cancer Technology reports compelling synergy between its

by GCT Admin

GCT-007 Plus Tamoxifen Synergistic Effect Treating Endocrine Therapy-Resistant Breast Cancer

For Immediate Release Contact: info@globalcancertechnology.com San Diego, CA – July

by GCT Admin

Global Cancer Technology Appoints Dr. Sanjeev Thohan as Chief Development Officer

Global Cancer Technology is a preclinical-stage biopharmaceutical company focused on advancing novel therapeutics for oncology. The company is currently raising investment capital to support its planned Phase I clinical trial.

by GCT Admin

Global Cancer Technology Secures Full Ownership of Groundbreaking Cancer-Fighting Patents

Global Cancer Technology has acquired full patent ownership for two potentially life-saving cancer treatments from Neuropore Therapies.

by GCT Admin

GLOBAL CANCER TECHNOLOGY FILES TO EXPAND IP PORTFOLIO

by GCT Admin

Pre-Clinical results from the University of Colorado shows GCT-007 more effective than Paxalisib TM at lower concentrations

by GCT Admin

Pre-Clinical data from the University of Wisconsin confirms GCT-007 has low toxicity properties and crosses the Blood Brain Barrier

by GCT Admin

GLOBAL CANCER TECHNOLOGY SHOWS PROMISING PRE-CLINICAL DATA WITH GCT-007 AND CHECKPOINT INHIBITOR TREATING TAMOXIFEN-RESISTANT BREAST CANCER

by GCT Admin

Global Cancer Technology’s GCT-007 receives promising pre-clinical results from the University of Colorado Anschutz Medical School

by GCT Admin

GLOBAL CANCER TECHNOLOGY PATENTS ISSUED IN JAPAN

by GCT Admin

GLOBAL CANCER TECHNOLOGY’S PI3K inhibitor drug shows promising preclinical results for the treatment of Glioblastoma multiforme (GBM)

by GCT Admin

GCT-007 CONTINUES TO RECEIVE EXCEPTIONAL GLIOBLASTOMA PRE-CLINICAL RESULTS

12/46